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Abstract: Preservation of the peritoneal membrane is an essential determinant of the long-term
outcome of peritoneal dialysis (PD). Epithelial-to-mesenchymal transition (EMT) plays a central role
in the pathogenesis of PD-related peritoneal membrane injury. We hypothesized that mitochondria
may be implicated in the mechanisms that initiate and sustain peritoneal membrane damage in
this setting. Hence, we carried out ex vivo studies of effluent-derived human mesothelial cells,
which disclosed a significant increase in mitochondrial reactive oxygen species (mtROS) production
and a loss of mitochondrial membrane potential in mesothelial cells with a fibroblast phenotype,
compared to those preserving an epithelial morphology. In addition, in vitro studies of omentum-
derived mesothelial cells identified mtROS as mediators of the EMT process as mitoTEMPO, a
selective mtROS scavenger, reduced fibronectin protein expression induced by TGF-ß1. Moreover,
we quantified mitochondrial DNA (mtDNA) levels in the supernatant of effluent PD solutions,
disclosing a direct correlation with small solute transport characteristics (as estimated from the ratio
dialysate/plasma of creatinine at 240 min), and an inverse correlation with peritoneal ultrafiltration.
These results suggest that mitochondria are involved in the EMT that human peritoneal mesothelial
cells suffer in the course of PD therapy. The level of mtDNA in the effluent dialysate of PD patients
could perform as a biomarker of PD-induced damage to the peritoneal membrane.
Keywords: peritoneal dialysis; epithelial-to-mesenchymal transition; oxidative stress; mitochondria;
mitochondrial DNA; biomarker; mesothelial cells
1. Introduction
Chronic kidney disease is a severe disorder that is reaching epidemic proportions [1].
Peritoneal dialysis (PD) is a growing therapeutic alternative for end-stage kidney disease [2].
In this technique, the peritoneum of the patient is used as a semipermeable membrane for
the exchange of water and solutes between the blood and different solutions introduced
(and periodically renewed) in the peritoneal cavity [3]. Unfortunately, long-term exposure
to these non-physiologic PD solutions, as well as to the peritoneal catheter, may lead
to progressive peritoneal membrane injury resulting in PD technique failure and even
mortality [4]. Mesothelial cells lining the peritoneal cavity represent the first line of contact
with PD fluids, and appear to play an active role in the loss of integrity of the peritoneal
membrane during PD therapy [5–8].
In response to PD, mesothelial cells can react by losing their epithelial phenotype,
acquiring myofibroblast-like characteristics through an epithelial-to-mesenchymal transi-
tion (EMT) process [7]. This process induces early pathological changes in the peritoneal
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membrane [9]. In addition, ex vivo studies have shown that these morphologic alterations
correlate with disorders of peritoneal membrane transport characteristics [10]. Several
molecular signaling pathways have been described to induce EMT, of which TGF-ß1 is
one of the most powerful [11]. During EMT, mesothelial cells experience a decrease in the
expression of epithelial markers, including E-cadherin, enhancing the expression of mes-
enchymal markers like fibronectin, collagen I or α-smooth muscle actin (α-SMA) [7]. As a
consequence, cells acquire invasive capacities and reach the submesothelial stroma, where
they produce extracellular matrix—but also inflammatory and angiogenic—factors, pro-
moting peritoneal oxidative stress, inflammation and, finally, fibrosis, affecting peritoneal
transport of water and solutes and resulting in ultrafiltration failure [6,12].
A large body of evidence supports the important role of oxidative stress in the peri-
toneal pathophysiology of patients undergoing PD. In fact, the presence of free radicals
in the effluent is associated with technique failure in stable PD patients [13,14]. Previous
studies have demonstrated that glucose-rich and/or acidic hypertonic PD solutions could
be associated with higher levels of oxidative stress [15–18]. The PD-related oxidative
process can be modulated by drug treatments used in these patients [19,20].
Mitochondria play a key role in oxidative stress since they represent the most im-
portant source of reactive oxygen species (ROS), but they are also targeted by these
molecules [21]. Besides, damaged mitochondria release damage-associated molecular
patterns (DAMPs, also known as alarmins), such as mtROS or mtDNA, which are rec-
ognized by the immune system and subsequently trigger an inflammatory and immune
response, which can also cause mitochondrial damage, thus perpetuating a vicious cycle of
mitochondrial alteration and activation of pathologic pathways [22].
Regarding PD, mitochondrial dysfunction is one of the main causes of glucose-rich-
dialysate-induced mtROS and apoptosis, as well as mtDNA damage in human peritoneal
mesothelial cells [23–25]. Plasma and dialysate mtDNA levels could perform as prog-
nostic markers for peritoneal membrane function and PD technique survival [26,27]. All
these considerations point to a potential involvement of mitochondrial dysfunction in the
structural and functional disorders appearing in the course of PD therapy, but the role of
mitochondria in the pathophysiology of PD-related peritoneal membrane damage has not
yet been adequately defined.
The purpose of the present study was to investigate the role of mitochondrial dys-
function in the damage that the peritoneal membrane suffers during the course of PD.
Secondarily, we explored the role of mtDNA as a potential biomarker of PD-induced
damage to the peritoneal membrane.
2. Materials and Methods
2.1. Study Population
The study was conducted according to the Spanish Law for Biomedical Research (Law
14/2007-3 of July), complied with the Helsinki declaration and its later amendments and
was approved by the local Ethics Committee (Galicia, Spain) (code number 2014/454).
Written informed consent was obtained from all patients included in the study, and samples
were coded to maintain anonymity. Demographic and clinical data were collected by
medical record review.
2.2. Culture and Cell Stimulation of Human Mesothelial Cells
Human mesothelial cells were obtained from PD effluents and from omentum samples
using standard methods described previously [10]. For ex vivo analysis, we collected peri-
toneal effluents from 118 patients treated with PD in the University Hospital of A Coruña.
Dialysate samples were obtained at the time of the initiation of PD therapy (new initia-
tion) or after overnight dwells, in the latter case simultaneously with routine performance
of peritoneal equilibration tests (PETs) with complete drainage at 60 min. All patients
were treated with low-glucose degradation product, bicarbonate-lactate buffered PD so-
lutions. Samples were categorized as new initiation (PD time = 0 months), short vintage
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(PD time < 4 months) and long vintage (PD time ≥ 4 months). After centrifugation at
1500 rpm for 10 min, the cell pellet was cultured in Roswell Park Memorial Institute (RPMI)
medium (Lonza, Basel, Switzerland) supplemented with 20% heat-inactivated fetal bovine
serum (FBS; ThermoFisher, Hillsboro, OR, USA), 100 U/mL penicillin, 100 µg/mL strepto-
mycin (Gibco, Hillsboro, OR, USA) and 0.12 U/mL human insulin (Novo Nordisk Pharma,
Madrid, Spain) until reaching the confluence. Mesothelial cells were characterized by
phase contrast microscopy (Nikon Eclipse TS100, Melville, NY, USA) according to their
EMT status as epithelial or fibroblast-like, as previously reported [7]. In relation to mem-
brane transport type, patients were classified as high, high-average, low-average and low
according to the levels of 4-h dialysate/plasma (D/P) creatinine at ≥81, 66–80, 51–65 and
≤50, respectively.
For in vitro studies, human omental mesothelial cells were obtained from omentum
from three non-PD patients who underwent unrelated elective abdominal surgery. The
tissue was washed in saline serum solution (Fresenious, Barcelona, Spain) before being
cut into pieces of about 4 mm2 and digested with trypsin-0.05% EDTA (ThermoFisher)
for 20 min at 37 ◦C with agitation. The resulting suspension was centrifuged at 1200 rpm
for 8 min and cells were grown in RPMI medium supplemented with 20% inactivated
FBS, 100 U/mL penicillin, 100 µg/mL streptomycin and 0.12 UI/mL human insulin.
TGF-β (1 ng/mL) (Abcam, Cambridge, UK) was used to induce EMT. The mitochondrial
antioxidant mitoTEMPO (10 µM) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was
used to scavenge mtROS.
2.3. Western Blotting Assay
Western blot analyses were performed utilizing standard procedures. Briefly, 35 µg
of isolated protein from cell lysates were loaded and resolved using standard 7.5 % SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were then trans-
ferred to polyvinylidene difluoride (PVDF) membranes (Immobilon P, Millipore, Billerica,
MA, USA) by electroblotting, which were blocked with fat-free milk and probed with
specific antibodies against E-cadherin (1:1000, BD Biosciences, San Diego, CA, USA) and
fibronectin (1:5000, abcam). Immunoreactive bands were detected by chemiluminescence
using corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies and
enhanced chemiluminescence (ECL) detection reagents (GE Healthcare, Bloomington, IL,
USA), and then digitized using the LAS 3000 image analyzer. Tubulin (1:5000, Sigma,
St. Louise, MO, USA) was used as loading control. Quantitative changes in band inten-
sities were evaluated using Image J software (version 1.50; National Institute of Health,
Maryland, WA, USA).
2.4. Mitochondrial ROS Detection
Mitochondrial ROS production was measured in mesothelial cells using MitoSOX Red
(Life Technologies, Hillsboro, OR, USA). The dye permeates the membrane and become
oxidized by superoxide exhibiting red fluorescence. Mesothelial cells from PD effluents
were seeded in 48-well plates until confluence, washed with PBS and loaded with MitoSOX
Red (0.8 ng/mL) in 200 µL of Hank’s Balanced Salt Solution (HBSS, Gibco, Hillsboro, OR,
USA) for 30 min at 37 ◦C. Cells were subsequently washed, trypsinized and centrifuged
and then fluorescence was measured by flow cytometry using a FACScalibur cytometer.
The analysis of the data was performed using CellQuest Pro 5.1 software.
2.5. Assessment of Mitochondrial Membrane Potential
Mitochondrial membrane potential was determined using the fluorescent dye tetram-
ethylrhodamine (TMRM, 250 nM) (Life Technologies). Polarized mitochondria accumulate
more fluorescent dye, whereas depolarized mitochondria (lower mitochondrial membrane
potential) retain less dye and, therefore, show lower fluorescence intensity. The fluores-
cence intensity was measured by flow cytometry using a FACScalibur cytometer (BD) and
the data obtained were analyzed by CellQuest Pro 5.1 software (BD).
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2.6. Dialysate mtDNA Level
Effluent samples from PD patients were centrifuged at 1500 rpm for 10 min, and 5 mL
of supernatant was saved and stored at−80 ◦C immediately. DNA was extracted from 1 mL
of supernatant using Circulating DNA Minikit (Danagen, Barcelona, Spain) according to the
manufacturer’s instructions. The level of mtDNA was performed by real-time qPCR for the
human mitochondrial 12S gene expression (forward 5′-CCACGGGAAACAGCAGTGAT-
3′, reverse 5′-CTATTGACTTGGGTTAATCGTGTGA-3′) (Sigma). The LightCycler 480
(Roche, Indianapolis, IN, USA) system was employed with the following cycling conditions:
denaturation step at 95 ◦C for 10 min, followed by 50 cycles at 95 ◦C for 10 s, 62 ◦C for
60 s and 72 ◦C for 5 s. The level of mtDNA copies was extrapolated into an external
standard curve developed from serial dilutions of mtDNA isolated from Tc28a2 cells and
was expressed as the mtDNA copy number/µL.
2.7. Statistical Analysis
Data were expressed as the mean ± SEM and a p-value of ≤0.05 was considered
significant. Ex vivo statistical analysis (mtROS, mitochondrial membrane potential and
mtDNA) was carried out using the SPSS 26 software (IBM, Manhattan, NY, USA). As the
data were not normally distributed, non-parametric tests were carried out. To compare
numerical values between two independent groups, the Mann–Whitney test was used;
however, to compare differences between more than two independent groups, the Kruskall–
Wallis test was performed. In the case of categorical data, the Chi-square test was applied.
Finally, correlations between numerical variables were analyzed with Spearman’s test. The
in vitro analysis was performed with GraphPad PRISM 7 software (GraphPad Software,
San Diego, CA, USA) using the non-parametric Mann–Whitney test.
3. Results
3.1. Mitochondrial Dysfunction during the Epithelial-to-Mesenchymal Transition of Mesothelial
Cells in PD Patients Ex Vivo
We tested the hypothesis that mitochondrial dysfunction could be involved in the
epithelial-to-mesenchymal transition of human peritoneal mesothelial cells, a key process
in peritoneal membrane failure. Firstly, effluent-derived mesothelial cells from 67 PD
patients were classified as epithelial and non-epithelial according to their phenotype at
confluence (Figure 1A). Secondly, as seen in Figure 1B,C, protein expression studies of ep-
ithelial marker E-cadherin and mesenchymal marker fibronectin were carried out, showing
that cells with epithelial phenotype had a positive expression of E-cadherin, which was
almost completely absent in non-epithelial cells. By contrast, fibronectin protein expres-
sion in epithelial cells was scant, and significantly increased in cells with a non-epithelial
phenotype (Figure 1B,C). The baseline characteristics of the patients according to the mor-
phology of effluent-derived mesothelial cells are shown in Table 1. Thirdly, quantitative
studies performed by flow cytometry showed that effluent-derived mesothelial cells with a
non-epithelial phenotype produced a significantly higher level (p ≤ 0.05) of mtROS than
the epithelial ones (Figure 2A). Likewise, a significant decrease (p ≤ 0.05) of mitochondrial
membrane potential was observed in cells that suffered the EMT process (Figure 2B) as
assessed by decreased tetramethylrhodamine methyl ester staining. Furthermore, when
effluent-derived mesothelial cells were classified according to PD duration in new initiation
(PD time = 0 months) and PETs (PD time > 0 months), an increasing trend in the level
of mtROS (new initiation: 6.6 ± 0.6 vs. PETs: 9.0 ± 0.7) and a decrease of mitochondrial
membrane potential (new initiation: 280.4 ± 31.0 vs. PETs: 234.9 ± 10.4) were observed in
mesothelial cells derived from PET samples, but they did not reach statistical significance
when compared with mesothelial cells derived from new initiation patients.
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Table 1. Study population characteristics according to the morphology of effluent-derived
mesothelial cells.
Variable Total Epithelial Non-Epithelial p-Value
Number of samples 80 63 17 -
Number of patients 67 - - -
Age (years) 62.7 ± 1.7 62.0 ± 2.0 65.3 ± 3.6 0.466
Body mass index (Kg/m2) 27.6 ± 0.6 27.5 ± 0.7 28.1 ± 1.3 0.638
Male (%) 61.2 61.1 61.5 0.977
Diabetic (%) 38.8 37 46.2 0.545
Time on PD (months) 16.7 ± 2.6 14.2 ± 2.8 26.1 ± 5.7 0.006
New initiation/PET samples (%) 15.8/84.2 20.3/79.7 0/100 0.058
Short/long vintage patients (%) 39.1/60.9 44.7/55.3 23.5/76.5 0.126
Glomerular filtration rate
(mL/min) 6.2 ± 0.4 6.2 ± 0.5 6.5 ± 0.9 0.769
D/P Creatinine at 4 h 72.5 ± 1.1 72.1 ± 1.2 73.4 ± 2.7 0.484
D/D0 glucose at 4 h 28.5 ± 1.1 29.1 ± 1.1 26.9 ± 2.7 0.250
Na sieving (mM/L) 8.0 ± 0.6 7.9 ± 0.7 8.3 ± 1.1 0.632
Ultrafiltration (mL) 391.4 ± 29.0 409.0 ± 32.0 342.6 ± 63.9 0.243
Peritoneal transport status (%):
o Fast 14.1 8.5 29.4 -
o Fast-average 64.1 72.3 41.2 -
o Slow-average 21.9 19.1 29.4 -
o Slow 0 0 0 -
C-reactive protein (mg/dL) 0.7 ± 0.1 0.8 ± 0.1 0.4 ± 0.1 0.382
PD: peritoneal dialysis; PET: peritoneal equilibration test; D/P creatinine: dialysate/plasma
creatinine ratio; D/D0 glucose: dialysate glucose at 4 h dwell time to dialysis glucose at 0 h
dwell time ratio. Data are expressed as the mean ± SEM.
3.2. Mitochondrial Dysfunction during the Epithelial-to-Mesenchymal Transition of
Mesothelial Cells
The mitochondrial alterations during EMT were confirmed in vitro using TGF-β1, the
key molecule in the induction of EMT. As seen in Figure 3, fibronectin protein expression,
induced by TGF-β1 (1 ng/mL), was significantly reversed (p ≤ 0.05) by inhibiting mtROS
production when human mesothelial cells from omentum samples were first preincubated
with the mitochondria-targeted antioxidant mitoTEMPO (10 µM). Therefore, these results
further confirm the involvement of the mitochondria in the EMT process, since a reduction
in ROS production by this organelle is translated into a decrease in fibrosis.
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sition (EMT) in omentum-derived mesothelial cells. (A) Representative Western blot analysis of
fibronectin expression at 8 and 72 h in TGF-β1-treated mesothelial cells with and without Mito
TEMPO pretreatment and (B) quantification expressed in arbitrary units. Bars represent the fold
induction over untreated cells as means ± SEM of three indepe dent experiments. * p < 0.05 vs.
TGF-β1 and # p < 0.05 vs. Basal. PD: peritoneal dialysis; EMT: epithelial-to-mesenchy al transition.
3.3. Free mtDNA Is Highly Elevated in the Peritoneal Effluent from PD Patients’ New Initiation
Next, we measured mtDNA conc nt a ion in the dialysate fluid n 232 samples fr m
118 patients. Table 2 shows the demographic and clinical characteristics of patients clas-
sified according to time in PD in new initiation, short vintage and long vintage samples.
Surprisingly, as seen in Figure 4, the results obtained indicated that there was a significant
increase of mtDNA copy number in the effluent of the new initiation samples (1147 ± 334),
in relation to a longer duration of PD, compared to PET samples, both short (71 ± 22,
p ≤ 0.001) and long vintage (47 ± 10, p ≤ 0.0001). Relatedly, there was a negative and
significant correlation between free mtDNA levels and time in PD (Spearman’s Rho =
−0.367, p ≤ 0.001, n = 227). The differences observed in the mtDNA levels between
short and long vintage patients were not statistically significant (p = 0.63). No signifi-
cant differences were found between surgical and percutaneous catheter implants. Also,
no correlation was found between plasma PCR levels and dialysate free mtDNA levels
(Spearman’s Rho = −0.008, p = 0.913).
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Table 2. Demographic and clinical characteristics of patients classified according to time on PD in new initiation, short
vintage and long vintage samples.
Variable Total New Initiation Short Vintage Long Vintage p-Value
Number of samples 232 49 70 113 -
Number of patients 118 49 30 39 -
Age (years) 63.3 ± 1.3 61.5 ± 2.0 65.4 ± 2.6 63.9 ± 2.2 0.535
Body mass index (Kg/m2) 28.3 ± 0.5 28.9 ± 0.8 27.4 ± 1.0 28.3 ± 0.8 0.456
Male (%) 59.8 59.2 58.6 61.5 0.074
Diabetic (%) 37.3 38.8 40 33.3 0.818
Time in PD (months) 19.6 ± 1.8 0.3 ± 0.3 2.7 ± 0.1 37.7 ± 2.8 0.000
Epithelial/Non ephithelial (%) 78.3/21.7 100/0 84.4/15.6 66.1/33.9 -
Glomerular filtration rate
(mL/min) 5.8 ± 0.3 7.8 ± 1.1 7.8 ± 0.6 4.5 ± 0.3 0.000
D/P Creatinine 240 min 70.5 ± 0.8 - 71.4 ± 1.3 69.9 ± 1.0 0.351
D/D0 glucose 240 min 29.6 ± 0.7 - 28.0 ± 1.0 30.6 ± 1.0 0.184
Na sieving (mM/L) 8.0 ± 0.4 - 8.3 ± 0.6 7.8 ± 0.5 0.467
Ultrafiltration (mL) 431.6 ± 19.3 - 442.6 ± 33.1 424.7 ± 23.7 0.866
Peritoneal transport status (%)
o Fast 13.7 - 18.6 10.7 -
o Fast-average 57.7 - 52.9 60.7 -
o Slow-average 25.8 - 27.1 25 -
o Slow 2.7 - 1.4 3.6 -
C-reactive proten (mg/dL) 0.7 ± 0.1 0.7 ± 0.2 0.9 ± 0.2 0.6 ± 0.1 0.724
PD: peritoneal dialysis; D/P creatinine: dialysate/plasma creatinine ratio; D/D0 glucose: dialysate glucose at 4 h dwell time to dialysis
glucose at 0 h dwell time ratio. Data are expressed as the mean ± SEM.
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Figure 4. mtDNA levels in the peritoneal effluent from PD patients. Values are the mean ± SEM
mtDNA copy numbers of patients classified according to time in PD in new initiation (n = 49),
short vintage (n = 70) and long vintage (n = 113) samples. *** p < 0.001 vs. first connection.
PD: peritoneal dialysis.
3.4. Correlation Between free mtDNA in the Peritoneal Dialysate Effluent from Long Vintage
Patients and the Peritoneal Transport Rate
As a final step, we explored the potential relationship between mtDNA levels in spent
dialysate and peritoneal transport characteristics, estimated from the D/P creatinine ratio
and standardized ultrafiltration during the PET studies. To avoid interference from the
Antioxidants 2021, 10, 447 9 of 14
initial damage to the peritoneal membrane caused by catheter insertion, and considering
that PET studies performed in long vintage patients may be more representative of the long-
term peritoneal transport characteristics of the patients, this analysis was carried out only in
long vintage patient samples (time on PD > 4 months, 37.7± 29.4 (SD) months, n = 113). As
shown in Figure 5A, our results disclosed a positive correlation between dialysate mtDNA
copy number and the D/P creatinine ratio in long vintage patients (Spearman’s Rho = 0.309,
p ≤ 0.001, n = 112), although comparisons between different patient subsets, categorized
according to membrane transport characteristics and mtDNA levels, showed marked
differences amongst patients within the same transport type (Figure 5B). Furthermore, we
observed a negative correlation between dialysate mtDNA copy numbers and ultrafiltration
rates in long vintage patients (Spearman’s Rho = −0.251, p ≤ 0.01, n = 112).
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4. iscussion
There is a clear connection between mitochondrial damage, oxidative stress and
infla mation [21,28], as well as between chronic inflammation and fibrosis, including
peritoneal fibrosis [10,29]. According to this point of view, inflammation could antedate
membrane fibrosis, and even the relationship between these two processes could be bidi-
rectional, each one inducing the other [30,31]. In the last few years, several studies have
related mitochondrial impairment with peritoneal membrane damage in the course of PD
therapy [23,25]. However, the possible role of mitochondrial dysfunction in the EMT pro-
cess that mesothelial cells from peritoneal membrane suffer in patients treated with PD, as
well as in monitoring PD-induced damage to the peritoneal membrane, remains unknown.
Some of our present findings have not, to our knowledge, been reported so far.
Mesothelial cells play a relevant role in the structural and functional alterations affecting
the peritoneal membrane in the course of PD [7]. PD fluids cause by themselves the EMT
of mesothelial cells both in vivo and in vitro [32]. This is the first study to document
mtROS production and mitochondrial membrane potential in cultured human mesothe-
lial cells derived from PD effluent. On one hand, our ex vivo model shows that effluent
mesothelial cells with a non-epithelial phenotype undergo an increased production of
mtROS when compared to those displaying an epithelial phenotype. This finding suggests
that mesothelial cells, which have undergone EMT, are an important source of mtROS,
and could contribute to the peritoneal inflammatory response and, as a consequence, to
progression of membrane fibrosis, which is the main feature of peritoneal membrane in-
jury during PD [7,9]. In fact, when omentum-derived mesothelial cells were treated with
Antioxidants 2021, 10, 447 10 of 14
the mitochondria-targeted antioxidant mitoTEMPO, the protein fibronectin expression
induced by TGF-β1 was significantly decreased. These findings confirm ROS, and specif-
ically mtROS, as key mediators in the process of PD-mediated EMT. These results are
consistent with in vitro studies in other cell types, and also in mesothelial cells, showing
that TGF-β1 also increases the generation of mtROS, resulting in inflammatory response,
phenotype transition and, finally, fibrosis [19,20,29,33]. On the other hand, we also ob-
served a significant decrease of mitochondrial membrane potential in cells affected by EMT.
Overall, our results could indicate that mesothelial cells of PD patients suffer mitochon-
drial damage during PD treatment, causing an increase of mtROS and a depolarization
of the mitochondrial membrane. Remarkably, decline of mitochondrial membrane po-
tential is a feature of apoptotic cell death [34]. These results are consistent with previous
studies describing apoptotic mesothelial cells in the peritoneal effluent of PD patients
and dialysate-glucose-induced oxidative stress and mitochondrial-mediated apoptosis
in human peritoneal mesothelial cells [23,25]. Moreover, biocompatible PD fluids may
reduce apoptosis of mesothelial cells [24]. Other studies on lung epithelial cells reported
that reduction in mitochondrial respiration could lead to increased ROS and decreased
mitochondrial membrane potential [35]. A more recent study has described how inhibition
of hyperglycolysis in mesothelial cells prevents peritoneal fibrosis by suppressing EMT [12].
In this sense, TGF-β1 can be substituted for PD fluid to stimulate hyperglycolysis, sup-
pressing mitochondrial respiration in mesothelial cells, as well as dynamic mitochondrial
changes [12]. These findings underline the relevance of our findings with regard to the
effects of mitochondrial dysfunction.
The next set of experiments focused on the analysis of mtDNA concentration in
the PD effluent. Mitochondria have been recently identified as key sources of DAMPs
(mito-DAMPs), playing a crucial role in DAMP-modulated inflammatory and immune
responses [22,36]. Specifically, mtDNA is a marker of mitochondrial damage, and its
presence is indicative of mitochondrial lysis. mtDNA can be released following differ-
ent types of cell death, such as apoptosis [37]. mtDNA has been implicated in NLRP3
inflammasome activation, a cytosolic receptor that once activated induces the maturation
of the proinflammatory cytokines IL-1β and IL-18 [38]; and also in Toll-like membrane
receptors (TLRs) activation, resulting in an inflammatory response [39]. Interestingly, the
activation of TLR9 by mtDNA mediates TGF-β1-induced fibroblast activation in lung
tissue, potentially leading to fibrosis [40]. Regarding PD, plasma and dialysate mtDNA
levels have been pointed out as prognostic markers of PD patient survival and peritoneal
solute transport in short vintage patients, respectively [26,27]. Also, NLRP3 is involved in
PD-related peritonitis [38].
Considering that local intraperitoneal inflammation is an important determinant
of the peritoneal solute transport rate [41] and that the kinetics of peritoneal transport
are more representative of long-term peritoneal function in long than in short vintage
patients [42], our next step was to analyze in the former subset the relationship between
dialysate mtDNA concentration and peritoneal membrane transport characteristics. Our
data disclosed that stepwise increments in effluent mtDNA levels were associated with
faster solute transport rates and a decreasing capacity of ultrafiltration. The previous study
from Xie et al. also described dialysate cell-free mtDNA fragments as a marker of peritoneal
solute transport rate in peritoneal dialysis [26]. However, the median time of PETs in this
study was only 2.7 months after initiation of PD (taking in consideration samples from
the first PET analysis to 6 months of treatment). In contrast, the median time of PET in
our correlation study was 37.7 months after initiation of PD (PD time ≥ 4 months), which
allowed us to evaluate this parameter in the long term. Even though there is a statistically
significant direct correlation between the peritoneal solute transport rate and free mtDNA
levels in the PD effluent, the latter showed a marked variability amongst patients with
similar transport rates, suggesting that other factors, such as genetic predisposition or
diet, could influence the background properties of the peritoneal membrane [43–45]. In
support of our findings, it has been shown that mtDNA increases enhance endothelial
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permeability through different pathways [46]. Additionally, our results suggest a role for
mito-DAMPs as important therapeutic targets in conditions where inflammation increases
pathologically endothelial permeability, as in the case of PD [46]. Our findings are also
consistent with those obtained in idiopathic pulmonary fibrosis bronchoalveolar lavage
samples, which exhibit a high concentration of extracellular mtDNA [40]. Also, idiopathic
pulmonary fibrosis fibroblasts exhibit high concentrations of extracellular mtDNA, which
is able to induce fibrosis in normal human lung fibroblasts [40]. Additionally, dialysate
IL-6 concentration, representing local subclinical intraperitoneal inflammation, is a well-
known predictor of the small solute transport rate in PD [41]. Previous studies have
shown how dialysate mtDNA levels are significantly associated with IL-6 levels in short-
vintage PD patients [26]. Preliminary results from our group showed an increase in effluent
IL-6 and mtDNA levels in patients whose effluent-derived mesothelial cells were non-
epithelioid phenotype (unpublished data), although the differences did not reach statistical
significance. Likewise, a recent in vitro model shows how mito-DAMPs-treated peripheral
blood mononuclear cells secreted IL-6 that impaired mitochondrial respiration [47]. In this
regard, more studies are needed to understand the association between local inflammation,
the EMT process and peritoneal transport characteristics in the long term.
Our data disclosed markedly increased mtDNA copy numbers in the effluent of the
new initiation, as compared with samples obtained later in the course of PD. In agreement,
there was a significant inverse correlation between free mtDNA levels and time on PD.
No significant differences were found between short and long vintage patients. This
increase in mtDNA levels at the very inception of PD could reflect an acute response of the
peritoneum to tissue injury caused by the catheter insertion. This increase in the level of
free mtDNA could be a consequence of leukocyte rolling and extravasation by peritoneal
catheter insertion, acting as a foreign body [48]. In addition, there was no difference in
mtDNA levels between percutaneous and surgical placement (data not shown), although,
in this particular case, our analysis was hampered by a limited statistical power. On the
other hand, we were not able to detect an association between dialysate free mtDNA and
plasma C-reactive protein levels. This circumstance is not unexpected, as previous studies
have established the independence of plasma and dialysate inflammatory markers in PD
patients [41]. Alternatively, it is known that peritoneal cavity lavage reduces the presence
of mito-DAMPs in open abdomen patients, and it is possible that frequent peritoneal cavity
lavage during PD may lead to decreased systemic absorption of mito-DAMPs, thereby
reducing the risk of systemic inflammatory response syndrome [49]. It is also possible that
recurrent drainage of dialysate could be the reason why the high levels of mtDNA that
were observed in the new initiation did not reach the bloodstream and, consequently, why
the inflammatory response was reduced at the systemic level. The potential consequences
of the increased free mtDNA released at inception of PD are unclear, but could be relevant,
since mtDNA is able to trigger an inflammatory response followed by fibrosis and, lastly,
loss of integrity of the peritoneal membrane.
Our results provide evidence that mitochondrial dysfunction promotes EMT in
mesothelial cells of PD patients. Conversely, preserving mitochondrial activity could
suppress mesothelial EMT and peritoneal fibrosis. In this regard, it has recently been
showed how metformin, an inductor of autophagy, could prevent mtDNA release and
inhibit EMT and peritoneal fibrosis via a modulation of oxidative stress [19]. In addition,
the level of mtDNA in the dialysate could help to monitor PD-induced damage to the
peritoneal membrane, acting as an indicator of the dialytic capacity, as well as a marker
of the intraperitoneal inflammation. Overall, mitochondrial function preservation could
help to limit peritoneal membrane injury during PD, as well as EMT and fibrogenesis in
other organs. Clearly, more studies are required to elucidate the role of mitochondrial
dysfunction in the pathophysiology of peritoneum in PD patients.
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